<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129935</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM 2003-10</org_study_id>
    <nct_id>NCT00129935</nct_id>
  </id_info>
  <brief_title>EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer</brief_title>
  <official_title>Phase III Trial to Compare Epirubicin and Cyclophosphamide (EC) Followed by Docetaxel (T) to Epirubicin and Docetaxel (ET) Followed by Capecitabine (X) as Adjuvant Treatment, Node Positive Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomised phase III trial, to compare the efficacy and safety
      profiles of two types of adjuvant chemotherapy regimens for human epidermal growth factor
      receptor 2 (HER2) negative, node positive breast cancer patients.

      Control Arm: This includes 4 cycles of EC 90/600 mg/m2 day 1 every 3 weeks, followed by 4
      cycles of T 100 mg/m2 day 1 every 3 weeks.

      Experimental Arm: This includes 4 cycles of ET 90/75 mg/m2, day 1 every 3 weeks, followed by
      4 cycles of capecitabine 1250 mg/m2, twice a day, via oral intake, for 14 days, and then a
      one-week rest period.

      Premenopausal women with hormone receptor positive tumours must receive 5 years of tamoxifen
      after the end of chemotherapy.

      Postmenopausal women with hormone receptor positive tumours can receive tamoxifen or
      aromatase inhibitors (or both) after the end of chemotherapy.

      Patients may receive radiotherapy when clinically indicated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estimation of the 5-year disease-free survival in the control arm is 72%. The experimental
      arm is expected to increase the 5-year disease-free survival by 7% (up to 79%). With an alpha
      error of 0.05 and 80% power, 592 patients per arm are needed. Assuming a 17%
      post-randomization drop-out, 691 patients per arm are needed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2004</start_date>
  <completion_date type="Actual">April 4, 2019</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Disease-free Survival (DFS) Event</measure>
    <time_frame>5 years</time_frame>
    <description>A participant was considered to have had a DFS event if there was evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival (OS) Event</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A participant was considered to have had a OS event if patient died from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Experienced Adverse Events (AE)</measure>
    <time_frame>5 years</time_frame>
    <description>Safety was assessed by standard clinical and laboratory tests, and were evaluated using NCI-CTC criteria v2.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire: Number of Participants With Hair Loss</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Hair loss was assessed by the quality of life of the patients through the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer 23 (EORTC QLQ-BR23) profile questionnaire, question 4. The quality of life of the patients was evaluated before each cycle and at the end of treatment.
In questionnaire, raw scores range from 0 to 100 and a high score represents a high level of functioning or Health Related Quality of Life, excluding single-item scales in which high scores represent a high level of symptoms. A difference of 10 points on the scale over baseline value was classified as the minimum clinically meaningful change in both questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire: Number of Participants With Hair Loss Recovery</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Hair Loss Recovery was assessed by a specific Hair Toxicity Questionnaire were patients answered if the hair was less abundant than before, weaker than before or other.
The questionnaire was evaluated up to two years after the end of chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire: Time to Taking Off the Wig</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Time to taking off the wig was assessed by a specific Hair Toxicity Questionnaire were patients answered when they stop to use the wig.
The questionnaire was evaluated up to two years after the end of chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1384</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: EC-T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: ET-X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Arm A: EC-T</arm_group_label>
    <arm_group_label>Arm B: ET-X</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Arm B: ET-X</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>Arm A: EC-T</arm_group_label>
    <arm_group_label>Arm B: ET-X</arm_group_label>
    <other_name>Ellence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Arm A: EC-T</arm_group_label>
    <other_name>cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Histological diagnosis of operable invasive adenocarcinoma of the breast (T1-T3).
             Tumours must be HER2 negative. Time window between surgery and study randomization
             must be less than 60 days.

          -  Surgery must consist of mastectomy or conservative surgery with axillary lymph node
             dissection. Margins free of disease and ductal carcinomas in situ (DCIS) are required.
             Lobular carcinoma is not considered a positive margin.

          -  Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of
             disease. If sentinel node technique is used, sentinel node can be the only node
             affected. Patients belonging to the following classifications are eligible: TNM
             pathologic stage N1a, TNM pathologic stage N2a, TNM pathologic stage N3a.

          -  Status of hormone receptors in primary tumour. Results must be available before the
             end of adjuvant chemotherapy.

          -  Patients must not present evidence of metastatic disease. Status of HER2 in primary
             tumour, known before randomization. Patients with immune histochemistry (IHC) 0 or +1
             are eligible. For patients with IHC 2+, fluorescence in situ hybridization (FISH) is
             mandatory and result must be negative.

          -  Age &gt;= 18 and &lt;= 70 years old.

          -  Performance status (Karnofsky index) &gt;= 80.

          -  Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed,
             normal cardiac function must be confirmed by left ventricular ejection fraction
             (LVEF).

          -  Laboratory results (within 14 days prior to randomization):

               -  Hematology: neutrophils &gt;= 1.5 x 10^9/l; platelets &gt;= 100 x 10^9/l; hemoglobin &gt;=
                  10 mg/dl;

               -  Hepatic function: total bilirubin &lt;= 1 upper normal limit (UNL); serum
                  glutamic-oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase
                  (SGPT) &lt;= 2.5 UNL; alkaline phosphatase &lt;= 2.5 UNL. If values of SGOT and SGPT &gt;
                  1.5 UNL are associated to alkaline phosphatase &gt; 2.5 UNL, patient is not
                  eligible;

               -  Renal function: creatinine &lt;= 175 mmol/l (2 mg/dl); creatinine clearance &gt;= 60
                  ml/min;

               -  Pharmacogenetics: one blood sample is needed for single nucleotide polymorphism
                  (SNP) assessment.

          -  Complete stage workup during the 12 weeks prior to randomization (mammograms are
             allowed within a 20 week window). All patients must have a bilateral mammogram, thorax
             x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or
             alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is
             recommended for all patients. Other tests: as clinically indicated.

          -  Patients able to comply with treatment and study follow-up.

          -  Negative pregnancy test done in the 14 prior days to randomization.

        Exclusion Criteria:

          -  Prior systemic therapy for breast cancer.

          -  Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any
             malignancy.

          -  Prior radiotherapy for breast cancer.

          -  Bilateral invasive breast cancer.

          -  Pregnant or lactating women. Adequate contraceptive methods must be used during
             chemotherapy and hormone therapy treatments.

          -  Any T4 or M1 tumour.

          -  Axillary lymph nodes: patients belonging to the following classifications are
             excluded: TNM pathologic stage N1b, TNM pathologic stage N1c, TNM pathologic stage
             N2b, TNM pathologic stage N3b, TNM pathologic stage N3c.

          -  HER2 positive breast cancer (IHC 3+ or positive FISH result).

          -  Pre-existing grade &gt;= 2 motor or sensorial neurotoxicity (National Cancer Institute
             Common Toxicity Criteria version 2.0 [NCICTC v-2.0]).

          -  Any other serious medical pathology, such as congestive heart failure; unstable
             angina; history of myocardial infarction during the previous year; uncontrolled
             hypertension or high risk arrhythmias.

          -  History of neurological or psychiatric disorders, which could preclude the patients
             from free informed consent.

          -  Active uncontrolled infection.

          -  Active peptic ulcer; unstable diabetes mellitus.

          -  Previous or current history of neoplasms different from breast cancer, except for skin
             carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and
             without recurrence in the last 10 years; ductal in situ carcinoma in the same breast;
             lobular in situ carcinoma.

          -  Chronic treatment with corticosteroids.

          -  Contraindications for corticosteroid administration.

          -  Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor
             modulators (SERMs), either for osteoporosis treatment or for prevention. These
             treatments must stop before randomisation.

          -  Concomitant treatment with other investigational products; participation in other
             clinical trials with a non-marketed drug in the 20 previous days before randomization.

          -  Concomitant treatment with another therapy for cancer.

          -  Males.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico Universitario San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elda</name>
      <address>
        <city>Elda</city>
        <state>Alicante</state>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Municipal de Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Espíritu Santo</name>
      <address>
        <city>Santa Coloma De Gramenet</city>
        <state>Barcelona</state>
        <zip>08923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Vic</name>
      <address>
        <city>Vic</city>
        <state>Barcelona</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castellón De La Plana</city>
        <state>Castellón</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez de la Frontera</name>
      <address>
        <city>Jerez De La Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologikoa</name>
      <address>
        <city>Donostia-San Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial Donostia</name>
      <address>
        <city>Donostia-San Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Barbastro</name>
      <address>
        <city>Barbastro</city>
        <state>Huesca</state>
        <zip>22300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02066</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de los Lirios</name>
      <address>
        <city>Alicante</city>
        <zip>03804</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología de Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Unviersitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospial General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial Rodríguez Chamorro de Zamora</name>
      <address>
        <city>Zamora</city>
        <zip>49021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Zaragoza &quot;Lozano Blesa&quot;</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Click here for more information about this study: GEICAM 2003-10</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 11, 2005</study_first_submitted>
  <study_first_submitted_qc>August 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2005</study_first_posted>
  <results_first_submitted>August 26, 2019</results_first_submitted>
  <results_first_submitted_qc>October 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2019</results_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2 negative breast cancer</keyword>
  <keyword>Node positive breast cancer</keyword>
  <keyword>Adjuvant treatment</keyword>
  <keyword>Oral chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1,384 patients were recruited in 58 Spanish centers and randomized to receive EC-T (n=669) or ET-X (n=715). 5 patients received no treatment in the ET-X arm. 4 patients were not treated with the study medication to which they were randomized (n=3 EC-T arm; n=1 ET-X arm). 1,378 patients were evaluable for safety (n=667 and 711 respectively).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: EC-T</title>
          <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
Docetaxel
Epirubicin
Cyclophosphamide</description>
        </group>
        <group group_id="P2">
          <title>Arm B: ET-X</title>
          <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
Docetaxel
Capecitabine
Epirubicin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="669"/>
                <participants group_id="P2" count="715"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="633">2 patients crossed from arm A to B by error, and 1 patient received other treatment by error.</participants>
                <participants group_id="P2" count="623">1 patient crossed from arm B to A by error.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recurrence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Second primary</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Crossed to the other arm</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: EC-T</title>
          <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
Docetaxel
Epirubicin
Cyclophosphamide</description>
        </group>
        <group group_id="B2">
          <title>Arm B: ET-X</title>
          <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
Docetaxel
Capecitabine
Epirubicin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="669"/>
            <count group_id="B2" value="715"/>
            <count group_id="B3" value="1384"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="27" upper_limit="73"/>
                    <measurement group_id="B2" value="51" lower_limit="25" upper_limit="73"/>
                    <measurement group_id="B3" value="51" lower_limit="25" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="669"/>
                    <measurement group_id="B2" value="715"/>
                    <measurement group_id="B3" value="1384"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="669"/>
                    <measurement group_id="B2" value="715"/>
                    <measurement group_id="B3" value="1384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status (PS)</title>
          <description>The Karnofsky PS Index classify patients as to their functional impairment. The lower the Karnofsky score, the worse the survival.
100 to 80: Able to carry on normal activity and to work; no special care needed.
70 to 50: Unable to work; able to live at home and care for most personal needs; varying amount of assistance needed.
40 to 0: Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>PS 80</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS 90</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PS 100</title>
                  <measurement_list>
                    <measurement group_id="B1" value="582"/>
                    <measurement group_id="B2" value="629"/>
                    <measurement group_id="B3" value="1211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Premenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="382"/>
                    <measurement group_id="B3" value="731"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Postmenopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                    <measurement group_id="B2" value="333"/>
                    <measurement group_id="B3" value="653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Invasive Ductal Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="567"/>
                    <measurement group_id="B2" value="589"/>
                    <measurement group_id="B3" value="1156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Invasive Lobular Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histopathologic grade</title>
          <description>Cancer cells are given a Grade (G) when they are removed from the breast and checked under a microscope. The G is based on how much the cancer cells look like normal cells.
G1 or well differentiated (score 3, 4, or 5): cells are slower-growing, and look more like normal breast tissue.
G2 or moderately differentiated (score 6, 7): cells are growing at a speed of and look like cells somewhere between G1 and 3.
G3 or poorly differentiated (score 8, 9): cells look very different from normal and will probably grow and spread faster.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="338"/>
                    <measurement group_id="B3" value="645"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="478"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Breast surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mastectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="636"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Breast-conserving surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                    <measurement group_id="B2" value="388"/>
                    <measurement group_id="B3" value="748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axillary surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Lymphadenectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="618"/>
                    <measurement group_id="B2" value="676"/>
                    <measurement group_id="B3" value="1294"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sentinel node biopsy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Both</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pathologic tumor size</title>
          <description>Pathologic Tumor (pT) size describes the size of the tumour. Larger T is associated with inferior survival.
pT1: tumour is 2 centimetres (cm) across or less. pT2: tumour &gt;2 cm but &lt;5 cm across. pT3: tumour &gt;5 cm across.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>pT1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="666"/>
                  </measurement_list>
                </category>
                <category>
                  <title>pT2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="645"/>
                  </measurement_list>
                </category>
                <category>
                  <title>pT3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Regional lymph nodes</title>
          <description>Pathologic Node (pN) describes whether the cancer has spread to the Lymph Nodes (LN). Prognosis is better when cancer has not spread to the LN. The more LN that contain cancer, the poorer prognosis tends to be.
pN1: Micrometastasis or metastasis in 1 to 3 axillary LN. pN2: Metastasis in 4 to 9 axillary LN. pN3: Metastasis in 10 or more axillary LN</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>pN1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="450"/>
                    <measurement group_id="B2" value="463"/>
                    <measurement group_id="B3" value="913"/>
                  </measurement_list>
                </category>
                <category>
                  <title>pN2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="348"/>
                  </measurement_list>
                </category>
                <category>
                  <title>pN3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hormone receptor status</title>
          <description>A cancer is called hormonal receptor positive if it has receptors for progesterone or estrogen. This suggests that the cancer cells, like normal breast cells, may receive signals from progesterone or estrogen that could promote their growth.
If the cancer is hormone-receptor-negative (no receptors are present), then hormonal therapy is unlikely to work.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="571"/>
                    <measurement group_id="B2" value="594"/>
                    <measurement group_id="B3" value="1165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human epidermal growth factor receptor 2 (HER2) status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="592"/>
                    <measurement group_id="B2" value="647"/>
                    <measurement group_id="B3" value="1239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Disease-free Survival (DFS) Event</title>
        <description>A participant was considered to have had a DFS event if there was evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: EC-T</title>
            <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
Docetaxel
Epirubicin
Cyclophosphamide</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET-X</title>
            <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
Docetaxel
Capecitabine
Epirubicin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disease-free Survival (DFS) Event</title>
          <description>A participant was considered to have had a DFS event if there was evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="669"/>
                <count group_id="O2" value="715"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Survival (OS) Event</title>
        <description>A participant was considered to have had a OS event if patient died from any cause.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: EC-T</title>
            <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
Docetaxel
Epirubicin
Cyclophosphamide</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET-X</title>
            <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
Docetaxel
Capecitabine
Epirubicin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Survival (OS) Event</title>
          <description>A participant was considered to have had a OS event if patient died from any cause.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="669"/>
                <count group_id="O2" value="715"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Who Experienced Adverse Events (AE)</title>
        <description>Safety was assessed by standard clinical and laboratory tests, and were evaluated using NCI-CTC criteria v2.0</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A: EC-T</title>
            <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
Docetaxel
Epirubicin
Cyclophosphamide</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET-X</title>
            <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
Docetaxel
Capecitabine
Epirubicin</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Experienced Adverse Events (AE)</title>
          <description>Safety was assessed by standard clinical and laboratory tests, and were evaluated using NCI-CTC criteria v2.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="667"/>
                <count group_id="O2" value="711"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="665"/>
                    <measurement group_id="O2" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire: Number of Participants With Hair Loss</title>
        <description>Hair loss was assessed by the quality of life of the patients through the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer 23 (EORTC QLQ-BR23) profile questionnaire, question 4. The quality of life of the patients was evaluated before each cycle and at the end of treatment.
In questionnaire, raw scores range from 0 to 100 and a high score represents a high level of functioning or Health Related Quality of Life, excluding single-item scales in which high scores represent a high level of symptoms. A difference of 10 points on the scale over baseline value was classified as the minimum clinically meaningful change in both questionnaires.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>360 patients completed a questionnaire specifically on hair loss 1-2 years after the end of chemotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: EC-T</title>
            <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
Docetaxel
Epirubicin
Cyclophosphamide</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET-X</title>
            <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
Docetaxel
Capecitabine
Epirubicin</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire: Number of Participants With Hair Loss</title>
          <description>Hair loss was assessed by the quality of life of the patients through the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer 23 (EORTC QLQ-BR23) profile questionnaire, question 4. The quality of life of the patients was evaluated before each cycle and at the end of treatment.
In questionnaire, raw scores range from 0 to 100 and a high score represents a high level of functioning or Health Related Quality of Life, excluding single-item scales in which high scores represent a high level of symptoms. A difference of 10 points on the scale over baseline value was classified as the minimum clinically meaningful change in both questionnaires.</description>
          <population>360 patients completed a questionnaire specifically on hair loss 1-2 years after the end of chemotherapy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete hair loss</title>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial hair loss</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No hair loss</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire: Number of Participants With Hair Loss Recovery</title>
        <description>Hair Loss Recovery was assessed by a specific Hair Toxicity Questionnaire were patients answered if the hair was less abundant than before, weaker than before or other.
The questionnaire was evaluated up to two years after the end of chemotherapy.</description>
        <time_frame>Up to 30 months</time_frame>
        <population>360 patients completed a questionnaire specifically on hair loss 1-2 years after the end of chemotherapy. Arm A: 174 and Arm B 184 patients suffer hair loss</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: EC-T</title>
            <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
Docetaxel
Epirubicin
Cyclophosphamide</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET-X</title>
            <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
Docetaxel
Capecitabine
Epirubicin</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire: Number of Participants With Hair Loss Recovery</title>
          <description>Hair Loss Recovery was assessed by a specific Hair Toxicity Questionnaire were patients answered if the hair was less abundant than before, weaker than before or other.
The questionnaire was evaluated up to two years after the end of chemotherapy.</description>
          <population>360 patients completed a questionnaire specifically on hair loss 1-2 years after the end of chemotherapy. Arm A: 174 and Arm B 184 patients suffer hair loss</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less abundant than before</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Weaker than before</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire: Time to Taking Off the Wig</title>
        <description>Time to taking off the wig was assessed by a specific Hair Toxicity Questionnaire were patients answered when they stop to use the wig.
The questionnaire was evaluated up to two years after the end of chemotherapy.</description>
        <time_frame>Up to 30 months</time_frame>
        <population>There is only information about take off the wig in 241 patients: Arm A: 111 and Arm B 130</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: EC-T</title>
            <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
Docetaxel
Epirubicin
Cyclophosphamide</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET-X</title>
            <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
Docetaxel
Capecitabine
Epirubicin</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire: Time to Taking Off the Wig</title>
          <description>Time to taking off the wig was assessed by a specific Hair Toxicity Questionnaire were patients answered when they stop to use the wig.
The questionnaire was evaluated up to two years after the end of chemotherapy.</description>
          <population>There is only information about take off the wig in 241 patients: Arm A: 111 and Arm B 130</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.35" lower_limit="0.62" upper_limit="61.35"/>
                    <measurement group_id="O2" value="6.03" lower_limit="1.48" upper_limit="19.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study treatment up to 30 days after last study dose, up to 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A: EC-T</title>
          <description>Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
Docetaxel
Epirubicin
Cyclophosphamide</description>
        </group>
        <group group_id="E2">
          <title>Arm B: ET-X</title>
          <description>Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
Docetaxel
Capecitabine
Epirubicin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE v. 2.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia / infarction</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia / infarction</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Conduction abnormality/ Atrioventricular heart block</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula anal</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Stomach flu</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Abdominal pain and hematuria</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Mucositis / Stomatitis</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Pancreatic adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Bone Fracture</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Breast implant repeled</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Infection with grade 3 or 4 neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Phenytoin poisoning interaction with capecitabine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Progression disease, carcinomatosis meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration-anxiety agitation</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteral obstruction</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Pneumonitis/Pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Thoracic pain</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand foot skin reaction</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Epidermis necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI-CTCAE v. 2.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="665" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="699" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHILS/GRANULOCYTES</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>NEUTROPHILS/GRANULOCYTES</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>NEUTROPHILS/GRANULOCYTES</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES (TOTAL WBC)</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES (TOTAL WBC)</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES (TOTAL WBC)</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>STOMATITIS/PHARYNGITIS (ORAL/PHARYNGEAL MUCOSITIS)</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="285" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="270" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>INFECTION WITHOUT NEUTROPENIA</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>IRREGULAR MENSES</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HAND-FOOT SKIN REACTION</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>HAND-FOOT SKIN REACTION</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="562" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="569" subjects_at_risk="715"/>
              </event>
              <event>
                <sub_title>NAIL CHANGES</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="715"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scientific Director / Medical Lead / Project Manager</name_or_title>
      <organization>Spanish Breast Cancer Research Group</organization>
      <phone>+34916592870</phone>
      <email>geicam@geicam.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

